Investor relations

We are a leading mental health company enabling safe access to psychedelic medicine through a network of psychiatry clinics and clinical research sites.

CSE:NM

Novamind Inc.

Share capitalization
Issued & outstanding: 42,835,901
Dilutive securities: 6,325,292

Canadian Securities Exchange
Latest Novamind
presentation
View presentation
Latest Novamind
fact sheet
View fact sheet

Financial statements

YearQuarterDateReportDownload
2022Q1November 29, 2021Management’s Discussion and Analysis View PDF
2022Q1November 29, 2021Interim Financial Statements View PDF
2021Q4November 4, 2021Audited Annual Financial Statements View PDF
2021Q4November 4, 2021Management’s Discussion and Analysis View PDF
2021Q3June 1, 2021Interim Financial Statements View PDF
2021Q3June 1, 2021Management’s Discussion and Analysis View PDF
2021Q2March 1, 2021Interim Financial Statements View PDF
2021Q2March 1, 2021Management’s Discussion and Analysis View PDF

Management’s Discussion and Analysis

November 29, 2021

View PDF

Q12022

Interim Financial Statements

November 29, 2021

View PDF

Q12022

Audited Annual Financial Statements

November 4, 2021

View PDF

Q42021

Management’s Discussion and Analysis

November 4, 2021

View PDF

Q42021

Interim Financial Statements

June 1, 2021

View PDF

Q32021

Management’s Discussion and Analysis

June 1, 2021

View PDF

Q32021

Interim Financial Statements

March 1, 2021

View PDF

Q22021

Management’s Discussion and Analysis

March 1, 2021

View PDF

Q22021

Advisors

Transfer agent

Marrelli Trust Company Limited

Legal Counsel

McMillan LLP

Auditor

DMCL LLP